Six Points of Miscommunication Between Oncologists and Pathologists

Slideshow

Regardless of where you practice, good communication between you and your pathologist is the best way to ensure that correct testing is done. Here are six common points of miscommunication to watch out for.

References:

1. Janne PA. What Are We Talking About: Next-Generation Sequencing, Sanger Sequencing, etc. Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting.

2. Aisner D. Tissue is the Issue: The Pathologist’s Role in Facilitating Molecular Analysis. Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting.

3. Nowak JA. The Practitioner's Guide to Using Molecular Testing. Presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
2 experts in this video
Related Content